Table 1 Baseline characteristics by study group
Control (N = 1129) | Intervention (N = 1070) | P value | |
|---|---|---|---|
Age (years) | 75.7 (8.2) | 75.6 (8.2) | 0.88 |
Gender (N (%) male) | 1106 (98.0) | 1054 (98.5) | 0.34 |
Race (N (%) black) | 56 (5.0) | 62 (5.8) | 0.39 |
Comorbidities (N (%)) | |||
Diabetes | 539 (47.7) | 545 (50.9) | 0.13 |
Hypertension | 958 (84.9) | 925 (86.4) | 0.29 |
Coronary artery disease | 139 (12.3) | 133 (12.4) | 0.9 |
Heart failure | 73 (6.5) | 64 (6.0) | 0.64 |
Systolic blood pressure (mmHg) | 130.1 (18) | 131.0 (18) | 0.20 |
Diastolic blood pressure (mmHg) | 70.5 (9.9) | 70.7 (9.9) | 0.68 |
Blood pressure > 130/80 (N (%)) | 473 (41.9) | 474 (44.3) | 0.26 |
eGFR (mL/min/1.73 m2) | 34.5 (7.3) | 34.2 (7.7) | 0.32 |
eGFR (N (%)) | |||
>30 mL/min/1.73 m2 | 880 (78.2) | 807 (75.8) | |
20-30 mL/min/1.73 m2 | 194 (17.2) | 192 (18.0) | 0.21 |
<20 mL/min/1.73 m2 | 52 (4.6) | 66 (6.2) | |
Proteinuria (N (%))* | 179 (15.9) | 200 (18.7) | 0.08 |
Measured in the past year (N (%)) | |||
PTH | 161 (14.3) | 157 (14.7) | 0.78 |
Phosphorus | 586 (51.9) | 561 (52.4) | 0.81 |
Ualb/Cr ratio | 504 (44.6) | 483 (45.1) | 0.81 |
Classes of antihypertensives (N (%))† | |||
0 | 37 (3.9) | 41 (4.4) | |
1 | 95 (9.9) | 86 (9.3) | |
2 | 247 (25.8) | 226 (24.4) | 0.78 |
3 | 284 (29.6) | 295 (31.9) | |
4+ | 295 (30.8) | 277 (29.9) | |
Medication Adherence | 1.3 (1.4) | 1.2 (1.3) | 0.61 |
Quality of Life (phone survey) | |||
SF12 MCS | 49.8 (10.7) | 49.5 (12.3) | 0.88 |
SF12 PCS | 36.8 (11.2) | 39.3 (10.9) | 0.12 |
KDQOL Burden | 76.5 (25.9) | 75.5 (27.1) | 0.80 |
KDQOL Effects | 84.4 (15.0) | 85.3 (15.2) | 0.67 |